US 6,982,259 B2
N-heterocyclic derivatives as NOS inhibitors
David D. Davey, El Sobrante, Calif. (US); Raju Mohan, Encinitis, Calif. (US); Gary B. Phillips, Pleasant Hill, Calif. (US); Guo Ping Wei, San Ramon, Calif. (US); and Wei Xu, Danville, Calif. (US)
Assigned to Schering Aktiengesellschaft, Berlin (Germany)
Filed on Apr. 23, 2003, as Appl. No. 10/422,185.
Claims priority of provisional application 60/377274, filed on Apr. 30, 2002.
Prior Publication US 2004/0023950 A1, Feb. 05, 2004
Int. Cl. C07D 401/10 (2006.01); C07D 403/10 (2006.01); A61K 31/4164 (2006.01); A61K 31/454 (2006.01); A61P 9/04 (2006.01)
U.S. Cl. 514—217.08 15 Claims
 
1. A compound selected from formula (I)
OG Complex Work Unit Drawing
wherein:
n is 0 to 2;
m is 0 to 1;
p is 0 to 2;
A1 is —O—, —CH2O— or —N(R6)—;
R1 is (1,3-benzodioxol-5-yl)alkyl (where the benzodioxolyl radical is optionally substituted by one or more substituents selected from the group consisting of alkyl, hydroxy, and alkoxy);
or R1 is (1,3-benzodioxol-5- yl)carbonyl (where the benzodioxolyl radical is optionally substituted by one or more substituents selected from the group consisting of alkyl, hydroxy, and alkoxy):
R2 is halo, haloalkyl, alkyl, or —OR6;
R3 is hydrogen or alkyl;
each R4 is independently alkyl, halo, haloalkyl, hydroxy, alkoxy, amino, dialkylamino, monoalkylamino, nitro, carboxy, alkoxycarbonyl, aminocarbonyl, monoalkylaminocarbonyl, or dialkylaminocarbonyl; and
R6 is hydrogen or alkyl;
as a single stereoisomer, a mixture of stereoisomers, or as a racemic mixture of stereoisomers; or a pharmaceutically acceptable salt thereof.